DCOY

distress 6/10 · elevated risk

$5.03+2%today-97% from 52w high

decoytx.com11 employeesHouston, TXBiotechnology

Revenue

pre-revenue

Liquidity

$8M

Runway

1.2 yrs

Shares 1y

-93%

Price & events

-44.2% over 6M

CatalystRating changeDilutionFinancingdashed = today

+1.7%

-16.0%

-16.1%

-7.2%

-46.2%

-96.0%

-98.9%

-100.0%

All

Overview

Market Cap: $2.68M
Volume: 1.92K
52 Week Range: $4.41 – $180
Total Shares: 531.97K
Float Shares: 528.86K
Short %: 29.56%
% Held by Insiders: 0.28%
% Held by Institutions: 5.76%
RVOL: 0.00x
Beta: 0.59

Pipeline · 0 trials · 0 upcoming

Readout	Phase	Drug	Indication	Enroll	Status
No pipeline trials tracked.

Catalyst news & presentations · 1

2025-11-13partnershipCompleted strategic merger with Decoy Therapeutics, Inc.SEC 8-K

Approved drugs (0)

none — clinical-stage

Capital structure — dilution & financing

Shares out: 531,968 · 6 offerings/1y · 3 PIPEs

2026-07-17424B3offering
2026-07-17EFFECTshelf_effective
2026-07-10S-1shelf_registration
2026-06-298-Kprivate_placement
2026-06-24EFFECTshelf_effective
2026-06-15S-1shelf_registration
2025-11-138-Kprivate_placement

🔒 Positioning — Pro

Short interest / days-to-cover, insider buys & sells.

Upgrade to Pro

🔒 Top holders — Pro

Institutional ownership + quarter-over-quarter accumulation/trimming.

Upgrade to Pro

Wall St ratings

no consensus

2026-01-23Ladenburg ThalmannBuy

Competitors

none identified